Predictive value of 18F-FDG PET/CT multi-metabolic parameters and tumor metabolic heterogeneity in the prognosis of gastric cancer

被引:2
|
作者
Wang, Jianlin [1 ,2 ]
Yu, Xiaopeng [1 ,2 ]
Shi, Aiqi [3 ]
Xie, Long [1 ,2 ]
Huang, Liqun [1 ,2 ]
Su, Yingrui [1 ,2 ]
Zha, Jinshun [1 ,2 ]
Liu, Jiangyan [3 ]
机构
[1] Fujian Med Univ, Dept Nucl Med, Affiliated Hosp 2, Quanzhou 362018, Peoples R China
[2] Fujian Med Univ, Clin Sch 2, Affiliated Hosp 2, Quanzhou 362018, Peoples R China
[3] Lanzhou Univ, Dept Nucl Med, Hosp 2, Cuiyingmen 82, Lanzhou 730030, Peoples R China
关键词
Gastric cancer; F-18-FDG PET; CT; Metabolic parameters; Metabolic heterogeneity; Prognosis; POSITRON-EMISSION-TOMOGRAPHY; INTRATUMORAL HETEROGENEITY; FDG PET/CT; ANGIOGENESIS; METASTASIS; DEFINITION; NOMOGRAM; MRI;
D O I
10.1007/s00432-023-05246-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveWe aimed to investigate the predictive value of pre-treatment F-18-FDG PET/CT multi-metabolic parameters and tumor metabolic heterogeneity for gastric cancer prognosis.MethodsSeventy-one patients with gastric cancer were included. All patients underwent F-18-FDG PET/CT whole-body scans prior to treatment and had pathologically confirmed gastric adenocarcinomas. Each metabolic parameter, including SUVmax, SUVmean, MTV, and TLG, was collected from the primary lesions of gastric cancer in all patients, and the slope of the linear regression between the MTV corresponding to different SUVmax thresholds (40% x SUVmax, 80% x SUVmax) of the primary lesions was calculated. The absolute value of the slope was regarded as the metabolic heterogeneity of the primary lesions, expressed as the heterogeneity index HI-1, and the coefficient of variance of the SUVmean of the primary lesions was regarded as HI-2. Patient prognosis was assessed by PFS and OS, and a nomogram of the prognostic prediction model was constructed, after which the clinical utility of the model was assessed using DCA.ResultsA total of 71 patients with gastric cancer, including 57 (80.3%) males and 14 (19.7%) females, had a mean age of 61 & PLUSMN; 10 years; disease progression occurred in 27 (38.0%) patients and death occurred in 24 (33.8%) patients. Multivariate Cox regression analysis showed that HI-1 alone was a common independent risk factor for PFS (HR: 1.183; 95% CI: 1.010-1.387, P < 0.05) and OS (HR: 1.214; 95% CI: 1.016-1.450, P < 0.05) in patients with gastric cancer. A nomogram created based on the results of Cox regression analysis increased the net clinical benefit for patients. Considering disease progression as a positive event, patients were divided into low-, intermediate-, and high-risk groups, and Kaplan-Meier survival analysis showed that there were significant differences in PFS among the three groups. When death was considered a positive event and patients were included in the low- and high-risk groups, there were significant differences in OS between the two groups.ConclusionThe heterogeneity index HI-1 of primary gastric cancer lesions is an independent risk factor for patient prognosis. A nomogram of prognostic prediction models constructed for each independent factor can increase the net clinical benefit and stratify the risk level of patients, providing a reference for guiding individualized patient treatment.
引用
收藏
页码:14535 / 14547
页数:13
相关论文
共 50 条
  • [21] Metabolic Characteristics and Diagnostic Contribution of 18F-FDG PET/CT in Gastric Carcinomas
    Arslan, Esra
    Aksoy, Tamer
    Gundogan, Cihan
    Sen, Cigdem
    Tatar, Selda Yilmaz
    Dursun, Nevra
    Cermik, Tevfik Fikret
    MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, 2020, 29 (01) : 25 - 32
  • [22] SPDL1 Overexpression Is Associated With the 18F-FDG PET/CT Metabolic Parameters, Prognosis, and Progression of Esophageal Cancer
    Liu, Hua-Song
    Guo, Qiang
    Yang, Heng
    Zeng, Min
    Xu, Li-Qiang
    Zhang, Qun-Xian
    Liu, Hua
    Guo, Jia-Long
    Zhang, Jun
    FRONTIERS IN GENETICS, 2022, 13
  • [23] Correlation between 18F-FDG PET/CT intra-tumor metabolic heterogeneity parameters and KRAS mutation in colorectal cancer
    Liu, Xin
    Wang, Shi-Cun
    Ni, Ming
    Xie, Qiang
    Zhang, Yi-Fan
    Lv, Wei-Fu
    Geng, Guang-Yong
    ABDOMINAL RADIOLOGY, 2022, 47 (04) : 1255 - 1264
  • [24] Diagnostic and Predictive Values of 18F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma
    Hong, Il Ki
    Lee, Jeong Mi
    Hwang, In Kyoung
    Paik, Seung Sook
    Kim, Chanwoo
    Lee, Seung Hyeun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6453 - 6465
  • [25] Added predictive value of 18F-FDG PET/CT for pediatric rhabdomyosarcoma
    El-Kholy, Esraa
    EL Nadi, Enas
    Hafez, Hanafy
    Ahmed, Soha
    Younes, Alaa
    EL-Kenanii, Naglaa
    Khalid, Elham
    NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (09) : 898 - 904
  • [26] Preoperative metabolic parameters of 18F-FDG PET/CT are associated with TNM stage and prognosis of colorectal cancer patients
    Lu, Xia
    Wang, Guanyun
    Feng, Lijuan
    Kan, Ying
    Wang, Wei
    Yang, Jigang
    Zhang, Mingyu
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2024, 14 (01) : 462 - 475
  • [27] Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma
    Albano, Domenico
    Bosio, Giovanni
    Bianchetti, Nicola
    Pagani, Chiara
    Re, Alessandro
    Tucci, Alessandra
    Giubbini, Raffaele
    Bertagna, Francesco
    ANNALS OF NUCLEAR MEDICINE, 2019, 33 (07) : 449 - 458
  • [28] Metabolic markers derived from 18F-FDG PET/CT in suspected recurrent ovarian carcinoma: predictive value for disease burden and prognosis
    Jain, Bela
    Khandelwal, Yogita
    Ora, Manish
    Mishra, Prabhakar
    Lal, Punita
    Gambhir, Sanjay
    NUCLEAR MEDICINE COMMUNICATIONS, 2025, 46 (03) : 268 - 275
  • [29] Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Surgically Treated Stage I Lung Adenocarcinoma Patients
    Tosi, Davide
    Pieropan, Sara
    Cattoni, Maria
    Bonitta, Gianluca
    Franzi, Sara
    Mendogni, Paolo
    Imperatori, Andrea
    Rotolo, Nicola
    Castellani, Massimo
    Cuzzocrea, Marco
    Schiorlin, Ilaria
    Casagrande, Sabrina
    De Palma, Diego
    Nosotti, Mario
    Dominioni, Lorenzo
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (08) : 621 - 626
  • [30] Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Splenic Marginal Zone Lymphoma
    Albano, Domenico
    Camoni, Luca
    Giubbini, Raffaele
    Bertagna, Francesco
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (11) : E897 - E904